KRAS and non-small cell lung carcinoma: It has previously been documented that the druggable mutation KRAS p.G12C is found in approximately 1% of EGFR-positive NSCLC patients progressing on a first-line treatment with an EGFR-TKI, and it tended to arise in tumors harboring EGFR uncommon mutations [44], supporting our findings.